EGFR and neoplasm: The mRT-PCR test tended to detect more CTCs (42.9%) among patients with an altered EGFR status of the primary tumour, including EGFR mutations, amplifications and high polysomy compared to patients with an EGFR wildtype status (17.4%, p = 0.091) (Fig. 4b).